Literature DB >> 12975371

Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions.

Paul A Voziyan1, Raja G Khalifah, Christophe Thibaudeau, Alaattin Yildiz, Jaison Jacob, Anthony S Serianni, Billy G Hudson.   

Abstract

Hyperglycemic conditions of diabetes accelerate protein modifications by glucose leading to the accumulation of advanced glycation end-products (AGEs). We have investigated the conversion of protein-Amadori intermediate to protein-AGE and the mechanism of its inhibition by pyridoxamine (PM), a potent AGE inhibitor that has been shown to prevent diabetic complications in animal models. During incubation of proteins with physiological diabetic concentrations of glucose, PM prevented the degradation of the protein glycation intermediate identified as fructosyllysine (Amadori) by 13C NMR using [2-13C]-enriched glucose. Subsequent removal of glucose and PM led to conversion of protein-Amadori to AGE Nepsilon-carboxymethyllysine (CML). We utilized this inhibition of post-Amadori reactions by PM to isolate protein-Amadori intermediate and to study the inhibitory effect of PM on its degradation to protein-CML. We first tested the hypothesis that PM blocks Amadori-to-CML conversion by interfering with the catalytic role of redox metal ions that are required for this glycoxidative reaction. Support for this hypothesis was obtained by examining structural analogs of PM in which its known bidentate metal ion binding sites were modified and by determining the effect of endogenous metal ions on PM inhibition. We also tested the alternative hypothesis that the inhibitory mechanism involves formation of covalent adducts between PM and protein-Amadori. However, our 13C NMR studies demonstrated that PM does not react with the Amadori. Because the mechanism of interference with redox metal catalysis is operative under the conditions closely mimicking the diabetic state, it may contribute significantly to PM efficacy in preventing diabetic complications in vivo. Inhibition of protein-Amadori degradation by PM also provides a simple procedure for the isolation of protein-Amadori intermediate, prepared at physiological levels of glucose for relevancy, to study both the biological effects and the chemistry of post-Amadori pathways of AGE formation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12975371     DOI: 10.1074/jbc.M307155200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Acetoacetate promotes the formation of fluorescent advanced glycation end products (AGEs).

Authors:  Mousa Bohlooli; Mansour Ghaffari-Moghaddam; Mostafa Khajeh; Zohre Aghashiri; Nader Sheibani; Ali Akbar Moosavi-Movahedi
Journal:  J Biomol Struct Dyn       Date:  2016-02-23

Review 2.  Targeting advanced glycation with pharmaceutical agents: where are we now?

Authors:  Danielle J Borg; Josephine M Forbes
Journal:  Glycoconj J       Date:  2016-07-09       Impact factor: 2.916

3.  Comparison of modification sites formed on human serum albumin at various stages of glycation.

Authors:  Omar S Barnaby; Ronald L Cerny; William Clarke; David S Hage
Journal:  Clin Chim Acta       Date:  2010-10-27       Impact factor: 3.786

4.  Pyridoxamine analogues scavenge lipid-derived gamma-ketoaldehydes and protect against H2O2-mediated cytotoxicity.

Authors:  Sean S Davies; Eric J Brantley; Paul A Voziyan; Venkataraman Amarnath; Irene Zagol-Ikapitte; Olivier Boutaud; Billy G Hudson; John A Oates; L Jackson Roberts
Journal:  Biochemistry       Date:  2006-12-06       Impact factor: 3.162

Review 5.  Red blood cell storage lesion: causes and potential clinical consequences.

Authors:  Tatsuro Yoshida; Michel Prudent; Angelo D'alessandro
Journal:  Blood Transfus       Date:  2019-01       Impact factor: 3.443

6.  Pyridorin in type 2 diabetic nephropathy.

Authors:  Edmund J Lewis; Tom Greene; Samuel Spitalewiz; Samuel Blumenthal; Tomas Berl; Lawrence G Hunsicker; Marc A Pohl; Richard D Rohde; Itamar Raz; Yair Yerushalmy; Yoram Yagil; Tommy Herskovits; Robert C Atkins; Anne T Reutens; David K Packham; Julia B Lewis
Journal:  J Am Soc Nephrol       Date:  2011-10-27       Impact factor: 10.121

7.  New dinitrosyl iron complexes bound with physiologically active dipeptide carnosine.

Authors:  Konstantin B Shumaev; Olga V Kosmachevskaya; Elvira I Nasybullina; Sergey V Gromov; Alexander A Novikov; Alexey F Topunov
Journal:  J Biol Inorg Chem       Date:  2016-11-22       Impact factor: 3.358

8.  Modification of collagen IV by glucose or methylglyoxal alters distinct mesangial cell functions.

Authors:  Ambra Pozzi; Roy Zent; Sergei Chetyrkin; Corina Borza; Nada Bulus; Peale Chuang; Dong Chen; Billy Hudson; Paul Voziyan
Journal:  J Am Soc Nephrol       Date:  2009-07-16       Impact factor: 10.121

9.  Pyridoxamine reduces postinjury fibrosis and improves functional recovery after acute kidney injury.

Authors:  Nataliya I Skrypnyk; Paul Voziyan; Haichun Yang; Christian R de Caestecker; Marie-Claude Theberge; Mathieu Drouin; Billy Hudson; Raymond C Harris; Mark P de Caestecker
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-18

10.  Regulation of glomerular endothelial cell proteoglycans by glucose.

Authors:  Tae-Sun Ha; Senthil Duraisamy; Jennifer L Faulkner; Balakuntalam S Kasinath
Journal:  J Korean Med Sci       Date:  2004-04       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.